Please ensure Javascript is enabled for purposes of website accessibility

John McCamant

John McCamant joined the Medical Technology Stock Letter as Associate Editor in 1987 and was named Editor of this leading investment newsletter in August 2000. Mr. McCamant has spent twenty five years on the front lines of biotechnology investing. As an equities analyst for the American Healthcare Fund, he uncovered investment opportunities and guided investment strategy. At Burrill & Company, a San Francisco-based private merchant bank, he was a lead in raising $75 million for a venture capital fund. Mr. McCamant has established an extensive network that includes contacts throughout the investment banking and venture capital communities. His expertise in biotechnology investments is a subject of media interest. He is frequently consulted and quoted by The Washington Post, Business Week, Reuters, Bloomberg, CBS Marketwatch.

From this author
The Medical Technology Stock Letter (MTSL) provides solid investment advice based on company and industry fundamentals. Our thirty years of experience in providing investment advice for this unique and volatile sector gives MTSL and YOU the edge. Our insistence on thorough research and knowledge of the forces moving the sector...